L-Tyrosine, 3-methoxy-
| Title | Journal |
|---|---|
| Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. | Brain research 20130225 |
| Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. | European journal of neurology 20120601 |
| Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats. | Biological & pharmaceutical bulletin 20120101 |
| Pyridoxal phosphate-responsive seizures in a patient with cerebral folate deficiency (CFD) and congenital deafness with labyrinthine aplasia, microtia and microdontia (LAMM). | Molecular genetics and metabolism 20111101 |
| Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. | Hiroshima journal of medical sciences 20110901 |
| Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. | Naunyn-Schmiedeberg's archives of pharmacology 20110601 |
| Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. | Movement disorders : official journal of the Movement Disorder Society 20110215 |
| Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. | Molecular genetics and metabolism 20101201 |
| Consumption of pasteurized human lysozyme transgenic goats' milk alters serum metabolite profile in young pigs. | Transgenic research 20100801 |
| Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). | Brain : a journal of neurology 20100701 |
| Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. | Movement disorders : official journal of the Movement Disorder Society 20100615 |
| Caffeic acid improves the bioavailability of L-dopa in rabbit plasma. | Phytotherapy research : PTR 20100601 |
| Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. | Clinical neuropharmacology 20100501 |
| Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. | PloS one 20100101 |
| Peripheral COMT inhibition prevents levodopa associated homocysteine increase. | Journal of neural transmission (Vienna, Austria : 1996) 20091001 |
| Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. | Clinical therapeutics 20091001 |
| Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20090715 |
| Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. | Sleep medicine 20090101 |
| The role of 3-O-methyldopa in the side effects of L-dopa. | Neurochemical research 20080301 |
| Simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and alpha-methyldopa by HPLC. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101 |
| Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. | Clinical neuropharmacology 20080101 |
| Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. | Drugs in R&D 20080101 |
| Acute levodopa administration reduces cortisol release in patients with Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20070301 |
| Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20070101 |
| Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20061001 |
| Determination, purity assessment and chiral separation of levodopa methyl ester in bulk and formulation pharmaceuticals. | Biomedical chromatography : BMC 20060901 |
| Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060519 |
| Clinical (video) findings and cerebrospinal fluid neurotransmitters in 2 children with severe chronic bilirubin encephalopathy, including a former preterm infant without marked hyperbilirubinemia VIDEO. | Pediatrics 20051101 |
| Concise synthesis of all stereoisomers of beta-methoxytyrosine and determination of the absolute configuration of the residue in callipeltin A. | Organic letters 20050804 |
| Effects of homocysteine on the dopaminergic system and behavior in rodents. | Neurotoxicology 20050601 |
| Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. | Neuroscience letters 20040617 |
| Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. | Behavioural brain research 20040505 |
| Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. | Neurology 20040413 |
| Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040405 |
| Interference of the electrospray voltage on chromatographic separations using porous graphitic carbon columns. | Journal of mass spectrometry : JMS 20040201 |
| Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. | European journal of clinical pharmacology 20031101 |
| Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20030801 |
| Sources and significance of plasma levels of catechols and their metabolites in humans. | The Journal of pharmacology and experimental therapeutics 20030601 |
| Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. | The European journal of neuroscience 20030601 |
| Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20030101 |
| Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. | Annals of the New York Academy of Sciences 20020601 |
| 3-OMD and homocysteine plasma levels in parkinsonian patients. | Journal of neural transmission (Vienna, Austria : 1996) 20020201 |
| COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) 20020101 |
| L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. | Experimental neurology 20010901 |
| Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. | Clinical chemistry 20010601 |
| Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. | The Journal of biological chemistry 20010518 |
| BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. | European journal of pharmacology 20010518 |
| Developmental changes in cerebrospinal fluid concentrations of monoamine-related substances in patients with dentatorubral-pallidoluysian atrophy. | Journal of child neurology 20010201 |
| The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. | The European journal of neuroscience 20010101 |
| Catechol-O-methyltransferase decreases levodopa toxicity in vitro. | Clinical neuropharmacology 20010101 |
| Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. | Clinical neuropharmacology 19990101 |
| Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. | Neuroscience letters 19950616 |
| The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. | Experientia 19941015 |
| 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse. | Pharmacology 19940401 |
| Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. | European neurology 19930101 |
| Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. | Journal of neural transmission. Supplementum 19900101 |
| Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. | Journal of neurology 19890501 |